ERNA stock Statistics — Ernexa Therapeutics Inc. filings, insiders & smart money

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2026-08-06 · filed common shares: 1.63M
Shares float: Sign in
Float %: Sign in
Insider ownership: —
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 1.21%
Short ratioDays to cover, as published by FINRA: 1.00
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 24.80%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 38.40%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Gross marginFY Dec 24: 83.51%
Operating marginFY Dec 24: -2693.13%
Net margin: —
EBITDA marginFY Dec 24: -2669.24%
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -320.72%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -176.39%

Cash & equivalentsas of Jun 26: $5.02M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $349.00K
Debt / equityas of Jun 26: 10.91%
Current ratioas of Jun 26: 2.01
Quick ratio: —
Operating cash flowTTM to Jun 26: -$8.83M
Free cash flowUnadjusted FCF = CFO − capex · FY Dec 24: -$16.20M
TTM revenue / diluted share: —